
About CVRx
CVRx is a publicly listed company based in Minneapolis (United States) founded in 2001. Implantable technology for hypertension and heart failure is developed. CVRx has raised $368.5 million across 9 funding rounds from investors including SVB, DaVita and Oxford Finance. The company has 206 employees. CVRx offers products and services including Barostim. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is CVRX, INC. Its competitors include Adona Medical, Element Science and Ancora Heart; 3 of its 3 listed competitors have raised funding.
Company details
CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the bodys cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.
- Annual Revenue$56.65 M (USD)10.45as on Dec 31, 2025
- Net Profit-$53.31 M (USD)11.1as on Dec 31, 2025
- EBITDA-$50.51 M (USD)14.2as on Dec 31, 2025
- Total Equity Funding$368.5M (USD)
in 9 rounds
- Latest Funding Round$50M (USD), Series F
Jul 2020
- InvestorsSVB
& 20 more
- Employee Count206
Products & Services of CVRx
CVRx offers a comprehensive portfolio of products and services, including Barostim.
Delivers electrical pulses to improve heart failure symptoms and quality of life.
Apps and channels of CVRx
its YouTube channel Barostim for Treatment of Heart Failure Symptoms has 60.4K subscribers and 30 videos.
Videos from CVRx
The most watched videos on CVRx's YouTube channel, Barostim for Treatment of Heart Failure Symptoms (60.4K subscribers). Click a video to play it here.
Funding Insights of CVRx
CVRx has successfully raised a total of $368.5M across 9 strategic funding rounds. The most recent funding activity was a Series F round of $50 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $368.5M
- Total Rounds 9
- Last Round Series F β $50M
- First Round $22M
(Jul 2003)
- Investors Count 21
All 9 funding rounds of CVRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $50M | Series F | β | Strategic Healthcare Investment Partners, Vensana Capital | |
| May 2019 | $75.4M | Series F | β | Johnson & Johnson Innovation | |
| Aug 2016 | $20M | Debt – Conventional | β | β | |
| Sep 2014 | $15M | Debt – Venture | β | β | |
| Jul 2013 | $42M | Series F | β | New Enterprise Associates, Johnson & Johnson Innovation – JJDC | |
| Jul 2008 | $84M | Series E | β | New Enterprise Associates, Johnson & Johnson Innovation – JJDC | |
| May 2007 | $65M | Series D | β | Johnson & Johnson Innovation – JJDC | |
| May 2006 | $30.1M | Series C | β | Thomas Weisel Partners | |
| Jul 2003 | $22M | Series B | β | β |
21 investors in total: 21 institutional.
Investors in CVRx
CVRx has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, DaVita and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Ysios Capital is recognized as a leading life sciences investor. | ysioscapital.com | Barcelona, Spain | ||
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Stage-agnostic investments in US life sciences are pursued. | actionpotentialvc.com | Palo Alto, United States | ||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Sightline Partners is focused on secondary buyouts and joint ventures in healthcare. | 2004 | sightlinepartners.com | Bloomington, United States | |
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital is invested in US life sciences companies. | kearnyvp.com | San Francisco, United States |
Investor details for CVRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CVRx
64 people are tracked at CVRx (13 in leadership, 6 in board & advisors, 45 in team); the tracked headcount is 206.
| Name | Role | Group |
|---|---|---|
Al Crouse | VP, Quality Assurance & Regulatory Affairs | Leadership |
Jared Oasheim | CFO | Leadership |
Paul Verrastro | Chief Marketing & Strategy Officer | Leadership |
Thomas Hengsteler | VP, European Sales & Marketing | Leadership |
Dean Bruhn-Ding | VP, Regulatory Affairs & Quality Assurance | Leadership |
Paul Pignato | VP of Operations | Leadership |
Jonelle Burnham | VP & General Counsel | Leadership |
Jon Kilzer | Director Of Financial Planning And Analysis | Leadership |
Matthew Dagley | Director Of Marketing And Development | Leadership |
Parker Knight | Regional Sales Director - Southeast | Leadership |
Joe Tsokanos | Senior Director Of Commercial Excellence And Acceleration | Leadership |
Michael Brown | Sales Director | Leadership |
Seth Wilks | Director Of Clinical Science | Leadership |
Kevin Hykes | Director | Board & advisors |
Martha Shadan | Director | Board & advisors |
Kirk Nielsen | Director | Board & advisors |
Ali Behbahani | Director | Board & advisors |
Joseph Slattery | Director | Board & advisors |
Mudit K. Jain | Board Of Directors, Chair Compensation Committee, Nom & Gov Committee | Board & advisors |
Ryan Billups | Senior Clinical Sales Representative | Team |
44 more people are available in the full profile.
Complete people profiles for CVRx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CVRx
CVRx is a publicly listed company on the NASDAQ with ticker symbol CVRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jun 2021
- Listed onNASDAQ: CVRX
- Listed entityCVRx, Inc.
- Exchange sectorHealth technology
- ISINUS1266381052
- Share price$1.36 (-8.11% on the day) · 2026-10-13
- Market capitalisation$36.2M
- EPS (diluted, trailing year)$-1.97
- Volume (last session)490,504
Financials of CVRx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $56.6M | -$53.3M | -$50.5M |
| 2024 | $51.3M | -$60.0M | -$58.9M |
| 2023 | $39.3M | -$41.2M | -$42.6M |
| 2022 | $22.5M | -$41.4M | -$42.1M |
| 2021 | $13.0M | -$43.1M | -$25.8M |
Detailed financial statements for CVRx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of CVRx
4 dated milestones of CVRx across 20 years, from founding to its latest funding, stage changes and deals.
- Founded CVRx is founded.
- Funding First funding round of $22.0M.
- Funding Latest funding round, Series F, of $50.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of CVRx
CVRx has 3 listed competitors in our database, 3 of them funded. They include Adona Medical, Element Science and Ancora Heart.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adonamed.com | 2017 | Campbell, United States | $71M | Medical devices for heart failure management are developed. | ||
| elementscience.com | 2013 | San Francisco, United States | $192.6M | Wearable patch defibrillators are developed for sudden cardiac arrest treatment. | ||
| ancoraheart.com | 2001 | San Francisco, United States | $151.26M | 89 | Minimally invasive ventriculoplasty system for heart failure and FMR |
Detailed competitors of CVRx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CVRx
The website of CVRx (cvrx.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▲ 6.7% vs previous month
Websites whose visitors overlap most with CVRx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
hfsa.org | hfsa.org | 100% | #808,435 | β | |
cardiovascularbusiness.com | cardiovascularbusiness.com | 96% | #301,603 | β | |
| myokardia.com | 70% | View details | |||
atacand-us.com | atacand-us.com | 62% | β | ||
heartfailure.org | heartfailure.org | 62% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 7 similar websites and full traffic analytics for CVRx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as CVRx (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cvrx
Complete news archive for CVRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CVRx
CVRx was founded in 2001 and raised its 1st funding round 2 years after it was founded.
CVRx is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
CVRx is a funded company, having raised a total of $368.5M across 9 funding rounds to date. The company's 1st funding round was a Series B of $22M, raised on Jul 2003.
CVRx has 206 employees.
Annual revenue of CVRx is $56.65M as on Dec 31, 2025.
CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the bodys cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.
CVRx's top competitors include Adona Medical, Element Science and Ancora Heart.
CVRx offers Barostim.
Yes, CVRx is publicly traded on NASDAQ under the ticker symbol CVRX.
CVRx has 21 investors. Key investors include SVB, DaVita, Oxford Finance, Frazier Healthcare Partners, and Piper Jaffray.
CVRx operates through Cvrx, Inc..
